ONE formation is a highly regulated process that generally restricts ossification to the skeleton, yet the molecular control of bonecell differentiation is not well understood. Progressive osseous heteroplasia (POH; number 166350 in Mendelian Inheritance in Man [MIM] , a catalogue of inherited diseases 1 ) is a rare disorder characterized by dermal ossification during childhood (Fig. 1A) , with progressive and extensive formation of heterotopic bone within deeper tissues ( Fig. 1B  and 1C ). [2] [3] [4] [5] [6] POH first appears during infancy with the eruption of islands of heterotopic bone in the re-B ticular dermis and subcutaneous fat. Over time, these ossified areas coalesce into plaques that may invade fascia, skeletal muscle, tendons, and ligaments, resulting in ankylosis of affected joints and focal retardation of the growth of involved limbs. 2, 3, 6, 7 Progression of dermal ossification into deep connective tissues is the defining feature of POH. 2, 8 POH is not associated with trauma, infection, or metabolic abnormalities and is distinct from fibrodysplasia ossificans progressiva (MIM number 135100). 8 POH may be either sporadic or inherited as an autosomal dominant trait. 2, 6 The lack of large, multigenerational families or a naturally occurring animal model has impeded gene identification. Reports of dermal and subcutaneous ossification in patients with Albright's hereditary osteodystrophy (AHO), 9 a complex disorder characterized by developmental defects and dysmorphologies, suggested the possibility of a common molecular basis for POH and AHO. 5 AHO-specific dysmorphologies are often associated with resistance to parathyroid hormone and with resistance to other hormones (in which case the disorder is referred to as pseudohypoparathyroidism type 1a). When AHO occurs without hormone resistance in families with pseudohypoparathyroidism type 1a, the disorder is described as pseudopseudohypoparathyroidism.
AHO is caused by heterozygous inactivating mutations in GNAS1, the gene for guanine nucleotidebinding protein (G protein) alpha stimulating activity polypeptide 1, that result in decreased expression or function of the alpha subunit of the stimulatory G protein (G s a ) of adenylyl cyclase. 9 Although heterotopic ossification in patients with AHO is milder and more superficial than that in patients with POH, the recent description 10 of inactivating GNAS1 mutations, decreased G s a activity, or both in two patients with features of both AHO and severe progressive hetero-topic ossification provided a further rationale to investigate GNAS1 as a candidate gene for POH.
METHODS

Subjects
We evaluated subjects from 18 unrelated kindreds with familial POH (6 cases) or sporadic POH (12 cases). The protocol was approved by the investigational review boards of the Children's Hospital of Philadelphia and the University of Pennsylvania, and written informed consent was obtained from the subjects or their parents. Patients from Families 3, 6 5, 12, and 13, 2 8, 3 11, 11 16, 12 and 18 13 have been previously described in case reports.
Polymerase-Chain-Reaction Amplification and Sequencing of Genomic DNA
Genomic DNA was isolated directly from blood or from EpsteinBarr virus-transformed lymphocyte lines with the use of DNA blood-isolation reagents (QIAamp, Qiagen, Valencia, Calif.); it was amplified with the use of oligonucleotide primers flanking exons 2 to 13 of the human GNAS1 gene 14 under previously reported polymerase-chain-reaction (PCR) conditions. 15 For exon 1, the primer pair 5'ATGGGCTGCCTCGGGAACAGTA (forward; beginning at the initiator codon) and 5'CCCTTACCCAGCAGCAG-CAGGC (reverse) was used for 40 cycles: 1 minute at 94°C, 40 seconds at 70°C, and 1 minute at 72°C. Each PCR reaction contained 200 ng of genomic DNA, each primer at a concentration of 0.4 µM, 0.08 mM deoxynucleoside triphosphates (Pharmacia, Piscataway, N.J.), 1.5 mM magnesium chloride, and 1.25 U of Taq polymerase (Life Technologies, Gaithersburg, Md.). Products were sequenced by the DNA Sequencing Core Facility of the University of Pennsylvania School of Veterinary Medicine.
RNA Isolation and Reverse Transcriptase-PCR Analysis
The total RNA from lymphoblastoid cell lines was isolated with use of Trizol reagent (Life Technologies), and poly(A) + RNA was Severe maculopapular lesions are evident, caused by extensive dermal and subcutaneous ossification in the left thigh, leg, foot, and heel. Similar involvement is evident anteriorly and in the proximal regions of both arms. There was less severe involvement in the right leg. Panel B shows the radiographic appearance of severe heterotopic ossification in POH. A lateral roentgenogram of the right leg of an 11-year-old girl from Family 8 shows severe heterotopic ossification of the soft tissues. There was extensive involvement of the entire right side of the body, including the jaw, neck, torso, abdomen, and pelvis, with ankylosis of joints of the axial and appendicular skeleton. Less severe involvement occurred at scattered sites on the left side of the body. Panel C shows an unenhanced computed tomographic image of the thighs of a 10-year-old boy from Family 14. The right thigh (R) was normal. The soft tissues of the left thigh were atrophied, and there was extensive soft-tissue ossification of the skin, subcutaneous fat, and quadriceps muscles that extended to the anterior cortex of the femur. In addition, the child had similar severe heterotopic ossification involving the left iliac crest and psoas muscle, as well as the entire left leg, with bony ankylosis of the left hip and left knee. Both Achilles tendons and the soft tissues of both heel pads contained extensive heterotopic ossification. The left leg was 4 cm shorter than the right. isolated with use of Micro-FastTrack reagents (Invitrogen, Carlsbad, Calif.). First-strand complementary DNA (cDNA) was synthesized from 1 µg of total RNA with the use of 12.5 µg of oligo-dT primer per milliliter and 1 mg of RNasin (Promega, Madison, Wis.) per milliliter, 5 U of SuperScript II reverse transcriptase (Life Technologies) per milliliter, 5 mM magnesium chloride, 10 mM dithiothreitol, and 1 mM deoxynucleoside triphosphates (Pharmacia) in a final volume of 10 µl at 42°C for 1 hour, followed by heat inactivation at 95°C for 10 minutes. First-strand cDNA (5 µl) was amplified by PCR with 1.5 mM magnesium chloride, 2.5 units of Amplitaq (Perkin-Elmer, Norwalk, Conn.), and 50 ng of each forward and reverse primer in a final volume of 20 µl for 40 cycles: one minute at 94°C, one minute at 53° to 72°C (optimized for each primer pair), and two minutes at 72°C. The products were gel-purified and sequenced as above. Primer pairs to amplify GNAS1 cDNA were designed with MacVector (Accelrys, San Diego, Calif.).
The GenBank accession numbers are AH002748 for GNAS1 human genomic DNA and NM000516 for GNAS1 human cDNA.
RESULTS
Inheritance Patterns in Families with POH
Subjects with POH from 18 unrelated families were examined (Fig. 2) . In four families (Families 1, 2, 3, and 4), children inherited POH from an affected father, a finding consistent with autosomal dominant inheritance. Two additional families (Families 5 and 18) had affected siblings with no affected parent. The severity and distribution of heterotopic ossification varied among affected members in each family; at least one affected person in each family had severe progressive heterotopic ossification during childhood, whereas other affected family members had dermal and subcutaneous ossification later in life, with slower pro- 
Identification of GNAS1 Mutations in Subjects with POH
Subjects with POH were screened for mutations in GNAS1 by PCR amplification and DNA sequencing of exons 1 to 13, all splice junctions, and some small introns. Heterozygous mutations were identified in 13 of 18 families: in 12 families, affected persons had small insertions, deletions, or tandem duplications that resulted in frame shifts predicted to cause premature termination of translation of the messenger RNA (mRNA) and loss of protein function (Fig. 3 and Table 1). In one family, Family 14, a single-nucleotide, G-to-C mutation altered the invariant AG dinucle- For each region of the GNAS1 gene in which a mutation was identified, sets of DNA sequencing chromatograms for normal GNAS1 genomic DNA from control subjects (lower panels) and mutated GNAS1 genomic DNA from control subjects (upper panels) are shown. Chromatograms from control subjects (lower panels) reveal a single DNA sequence from each region, demonstrating that the two alleles of the GNAS1 gene contain identical DNA sequences (represented by the single nucleotide sequence above each set of chromatogram peaks). In the patients (upper panels), by contrast, mutations that alter the DNA sequence of one of the two GNAS1 copies are revealed by a discordance or shift of the DNA sequence (as represented in the overlapping pattern of chromatogram peaks and by a second line of nucleotide sequence at the beginning of each discrepancy). In each panel, the specific position of the mutation within the GNAS1 gene is identified by the complementary DNA nucleotide number (n). Representative chromatograms are shown of frame-shift mutations due to insertions (ins) of nucleotides in the mutant allele (Panels A, D, and F), deletions (del) of nucleotides in the mutant allele (Panels B, C, and E), or tandem duplications (dupl; Panel H, 5 nucleotides duplicated; Panel I, 25 nucleotides duplicated). In Panel F, the reverse sequence is shown in the chromatograms. Panel G shows a one-nucleotide substitution at an acceptor splice site (¡1G → C). IVS 12 denotes intron (intervening sequence) 12. In Panels A through F, the arrow indicates the start of the frame-shifted sequence. In Panels H and I, the dashed line indicates the sequence that is duplicated in the region indicated by the solid line. otide of the intron 12 acceptor splice site (Fig. 3) . Mutation of the conserved AG dinucleotide to AC results in the use of a downstream AG as the acceptor site and production of a frame-shifted mRNA (data not shown).
No GNAS1 mutation was identified in 2 of 6 familial cases ( Fig. 2; Families 3 and 4 ) and 3 of 12 sporadic cases. Large deletions or rearrangements of the GNAS1 gene of these subjects were excluded by Southern blot analysis of genomic DNA.
Nonpenetrant GNAS1 Mutations in Families with POH
In four kindreds with POH, we examined genomic DNA from phenotypically normal parents of affected children for GNAS1 mutations. The clinically unaffected father in Family 5 (Fig. 2) had the same single-nucleotide deletion in exon 10 as his three affected daughters, indicating the absence of penetrance of this mutation in the father. Similarly, the unaffected father in Family 18 (Subject I-1 in Fig. 2 ) carried the same deletion in exon 7 that was identified in his five affected daughters. In both Family 5 and Family 18, the unaffected mother and the unaffected siblings did not have the mutation. By contrast, the single affected person in Family 6 (pedigree not shown) and Subject II-1 in Family 1 ( Fig. 2 and Table 1 ) presumably had new mutations, because none of their parents carried that mutation, although gonadal mosaicism in a parent is possible. With the exception of the unaffected fathers in Families 5 and 18, all affected subjects who were tested in families with inheritance of POH, but none of the unaffected subjects who were tested in such families, shared the same GNAS1 mutation.
Expression of GNAS1 mRNA in POH
According to reverse-transcriptase-PCR amplification of GNAS1 mRNA from 10 subjects with identified mutations, only 2 (from Families 2 and 14) had expression of both normal and mutant GNAS1 transcripts (Table 1) . Both subjects had a mutation near the 3' end of the gene: one was a frame shift in exon 13, and the other was an altered intron 12 acceptor splice site. The remaining eight subjects had only the normal mRNA sequence. This result indicated that mRNA from the mutant GNAS1 allele was not synthesized or was rapidly degraded, probably through nonsense-mediated decay, 16 a cellular mechanism causing the rapid turnover of mRNA that contains nonsense and frame-shift mutations.
Variable Expression of GNAS1 Mutations and Parental Inheritance Patterns
The same 4-bp deletion found in Families 1, 9, 11, and 18 has been identified as the basis for GNAS1 haploinsufficiency in several patients with AHO. 17 The 348delC frame-shift mutation identified in two subjects with POH from Families 6 and 12 (Table 1) has also been reported in a patient with AHO. 18 Thus, the identical mutations in GNAS1 can result in widely varying clinical phenotypes. All other GNAS1 mutations identified in patients with POH are unique.
Direct evidence of variable expression of the same GNAS1 mutation was observed within a single family, and the phenotype correlated with the parental origin of the mutant allele (Family 18 in Fig. 2 ). The proband (Subject II-8) had classic features of POH (severe cutaneous and subcutaneous ossification and progressive heterotopic ossification of skeletal muscle). Four of her five sisters had a milder POH phenotype. The proband and her affected siblings had a 4-bp frame-shift deletion in GNAS1 exon 7. The clinically unaffected father (Subject I-1) carried the mutation, but the unaffected mother did not, indicating inheritance of the mutant GNAS1 allele from a father with a nonpenetrant mutation. Nonpenetrance was also evident in Subject I-1 in Family 5. In both cases of fathers with nonpenetrant mutations, the parental origin of the mutated allele could not be determined. In Family 18, three children of the proband's sisters (Subjects III-3, III-7, and III-10 in Fig. 2 ) exhibited *Each mutation is identified by the complementary DNA nucleotide sequence of GNAS1. IVS 12 denotes intron (intervening sequence) 12. †Codon locations are those of the first codons altered by an insertion or duplication or codons containing deleted nucleotides. ‡For families with POH, Subjects II-1 and III-3 were examined in Family 1; Subject I-1 in Family 2; and Subjects I-1 and II-2 in Family 5. RNA from Families 7, 13, and 18 was not available for testing. A plus sign denotes expression of the normal allele, a minus sign expression of the mutant allele, and ND no data (RNA not available for study). features of AHO, including traces of subcutaneous ossification. Subcutaneous ossification was also noted in a fourth child (Subject III-6), who died suddenly at five months of age. 13 The two children available for examination (Subjects III-3 and III-7) carried the GNAS1 mutation. The findings in this family support the hypothesis that the parental origin of the mutant GNAS1 allele determines whether POH or AHO will develop in a child.
DISCUSSION
G proteins are members of a superfamily of guanosine triphosphate-binding proteins. 19 All members of this superfamily bind guanine nucleotides with high affinity and specificity, possess intrinsic guanosine triphosphatase activity, and function as molecular switches: they are "on" in the guanosine triphosphate-bound conformation and "off " after hydrolysis of guanosine triphosphate to guanosine diphosphate. The most clearly defined function of G proteins is in signal transduction. A large variety of extracellular first messengers, such as peptide and glycoprotein hormones, neurotransmitters, growth factors, chemotactic agents, and sensory signals, regulate cellular activity or function by binding to cell-surface receptors that are associated with G proteins. The G proteins act as timing switches to regulate the generation of intracellular second messengers, including cyclic AMP.
During the past decade, G proteins have been the focus of intense investigation, with particular interest in the investigation of G s , the stimulatory G protein of adenylyl cyclase, as a basis for human disease. 19 At least three disorders with features of dysregulated osteogenesis are associated with somatic or germ-line mutations in GNAS1, the gene that encodes G s a, the alpha subunit of G s . McCune-Albright syndrome is caused by postzygotic mutations that activate G s a and cause constitutive (hormone-independent) activation of adenylyl cyclase, 20 whereas AHO 9 and platelike osteoma cutis 21 are caused by inactivating germ-line GNAS1 mutations. We determined that another disorder of osteogenesis, POH, is due to inactivating mutations in the same gene.
Phenotypic expression of genetic disorders caused by single-gene mutations can be highly variable, most notably in autosomal dominant conditions. 22 Many of these disorders vary, either in the severity of a solitary abnormality or in the characteristic set of seemingly unrelated abnormalities, or in both. Inactivating mutations in GNAS1 have both these effects in AHO. Affected subjects have a wide range of developmental and somatic defects of variable severity, including subcutaneous ossification, skeletal dysmorphology, obesity, mental retardation, and hormone resistance. By contrast, patients with POH have a single characteristic disease manifestation (progressive heterotopic ossification) that can vary in its degree of severity.
In addition to variable expression in POH, we observed nonpenetrance (i.e., the complete failure of disease expression in some carriers of a gene mutation) in two families. Carriers of nonpenetrant GNAS1 mutations could have new mutations with a mosaic distribution that excludes cells that would express disease characteristics. Alternatively, nonpenetrance or variable expression could be due to influences from other genetic loci, epigenetic modifications, or environmental factors.
For several human genetic disorders, expression of the disease phenotype is influenced by whether the disease has been inherited from the father or the mother. Recent studies showing that maternal and paternal alleles of some genes do not function identically have helped clarify this phenomenon, known as imprinting. 23 A consistent difference between AHO and POH is the parental origin of the mutant GNAS1 allele. This is illustrated by Family 18, in which paternal inheritance of the mutant GNAS1 allele resulted in POH, and maternal inheritance resulted in AHO.
Previous clinical and molecular studies 9 have revealed that maternal transmission of GNAS1 mutations leads to the complete form of AHO, termed pseudohypoparathyroidism type 1a (MIM 103580), in which there is resistance to parathyroid hormone and other hormones whose receptors require G s a to stimulate adenylyl cyclase. By contrast, paternal inheritance of a GNAS1 mutation causes a less severe form of AHO, termed pseudopseudohypoparathyroidism (MIM 300800), in which the somatic defects are accompanied by normal hormone responsiveness. As in pseudopseudohypoparathyroidism, paternal inheritance of a mutant GNAS1 allele in patients with POH is associated with a lack of hormone resistance, but the two clinical phenotypes are otherwise clearly distinguishable. 8, 9 Molecular studies of the GNAS1 gene show monoallelic transcript expression according to the parent of origin, 24-27 a result consistent with parental imprinting. However, the manner of expression is far more complex than anticipated. In addition to a G s a-specific exon 1, three unique, alternative first exons are spliced to exons 2 through 13 of GNAS1. One of the alternative exons encodes the neurosecretory protein NESP55 and is expressed exclusively from the maternal allele, whereas the other two alternative first exons are transcribed only from the paternal allele. 24, 25, 28 Expression of the G s a-specific exon 1 appears to be biallelic in most tissues that have been examined, 24, 25, 29 although expression exclusively from the maternally derived allele has been documented in some tissues (e.g., murine renal cortex and adipose tissue 30 and human pituitary 31 ).
Given the complexity of transcript synthesis at the GNAS1 locus, it is not surprising that a wide variety of phenotypic effects results from GNAS1 mutations and that the phenotypes are influenced by the parent from whom the mutant allele is inherited. Hormone resistance (such as that in pseudohypoparathyroidism type 1a) is strongly correlated with mutations in the maternally derived allele, indicating that the maternal allele is critical (at least in some tissues) for cellular functions required for signal transduction. In contrast, severe, progressive heterotopic ossification, such as that found in POH, correlates with paternal inheritance of the GNAS1 mutation, suggesting that the paternal allele specifically influences progressive osteoblastic differentiation, proliferation of cells in soft connective tissues, or both.
Why paternal inheritance of a GNAS1 mutation should result in pseudopseudohypoparathyroidism in some families and POH in others is unclear. Other phenotypes that have been associated with GNAS1 inactivation (such as features of AHO -including mild dermal ossification -that occur in both pseudohypoparathyroidism type 1a and pseudopseudohypoparathyroidism) seem to be influenced by GNAS1 mutations in either the maternal or the paternal allele. Tissue and developmental specificity of imprinting at the GNAS1 locus is a plausible cause of the disparity among phenotypes. Overlapping patterns of variable expressivity (i.e., a range of phenotypic severity) by GNAS1 maternal, paternal, and biallelic transcripts may result in a complex set of phenotypes among patients with GNAS1-inactivating mutations.
Our findings expand the spectrum of phenotypic variability attributable to mutations in the GNAS1 gene and establishes GNAS1 as an important regulator of osteoblastic commitment in nonosteogenic connective tissues. Further investigation into imprinting effects and the regulation and function of the multiple transcripts of the GNAS1 locus will be required to understand the genotypic complexity and phenotypic variability associated with mutations at this locus.
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